medicexum
Regulatory & Commercial ConsultancyUnited Kingdom

The compliance
advantage in cannabis.

Medicexum is the regulatory and commercial partner for suppliers, importers and clinics building inside the UK's most scrutinised emerging market.

Send an email enquiryExplore our services
UK medicinal cannabis flower under regulated supply
CBMP · Schedule 2
EU GMP
Cannabis sativa L.
Trichome density 28%
UK Rx 2024+102%
Market 2028E£1.04B
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
UK Rx 2024+102%
Market 2028E£1.04B
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
UK Rx 2024+102%
Market 2028E£1.04B
MCR Patients60,000+
EU GMP partners12
Active clinics38
Compliance audits40+
Import routes9
Avg lead time14 days
01 — Market

The UK is the fastest-growing regulated cannabis market in Europe.

Demand is doubling. Regulation is tightening. Operators that treat compliance as competitive advantage will own the decade.

01CQC
0×
UK private prescriptions doubled in 2024
02Industry est.
£0.00B
Projected UK market value by 2028
03BMJ
0M
UK adults living with chronic pain
04YouGov
0%
Of UK adults open to medical cannabis
MHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedRP-Trained (Cogent Gold)Patient-FirstWholesale DealerBritish PharmacopoeiaMHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedRP-Trained (Cogent Gold)Patient-FirstWholesale DealerBritish PharmacopoeiaMHRA CompliantEU GMP SourcingHome Office LicensedGDP CertifiedRP-Trained (Cogent Gold)Patient-FirstWholesale DealerBritish Pharmacopoeia
02 — Services

A complete operating partner for cannabis-based medicinal products.

All services
01

Regulatory Compliance

MHRA, GDP and Home Office navigation. Audits, SOPs and Responsible Person frameworks.

02

Import & Export

EU GMP-compliant sourcing and licensed importation routes into the UK supply chain.

03

CBD & Novel Foods

FSA Novel Foods dossiers, public-list status, labelling and reformulation for UK CBD brands.

04

B2B Partnerships

Producers, importers and clinics matched into commercial relationships that scale.

05

Supply Chain Setup

Licence applications, storage, wholesale dealer obligations — stood up end-to-end.

06

Commercial Strategy

Pricing, positioning, go-to-market plans for new entrants and operators ready to scale.

03 — Position

Compliance is no longer a cost centre — it's the moat. The operators who treat MHRA, GDP and EU GMP as a strategic asset will define the UK market for the next decade.

Medicexum — Regulatory Perspective
04 — Evidence engine

We don't just quote the science.
We index it.

A live library of peer-reviewed cannabis research, regulatory bulletins and ongoing trials — graded, tagged and updated weekly. Built for clinicians, importers and policy teams who need evidence at hand.

Live · 356 studies indexed
Indexed cannabis research and regulatory bulletins
PubMedEurope PMCClinicalTrials.govNICEMHRAEMA
Grade CRegistered trial2029

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia

This registered trial is investigating whether transcranial direct current stimulation (tDCS) can help reduce cannabis use in 110 patients with co-occurring schizophrenia and cannabis use disorder. The study aims to measure changes in cannabis consumption, craving, addiction severity, schizophrenia symptoms, and overall functioning.

ClinicalTrials.govn=110
Grade CRegistered trial2029

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

This registered clinical trial is investigating whether a combined intervention can help young adults who experience problems with alcohol and cannabis use, as well as sleep difficulties, to reduce these issues. The study aims to recruit 800 participants to evaluate the effectiveness of this intervention.

ClinicalTrials.govn=800
Grade CRegistered trial2028

Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)

This registered trial is investigating carcinogen and toxicant exposure in young adults who use both e-cigarettes and cannabis. The study will measure nicotine, cannabis, and toxicant levels in blood and urine, alongside assessing user behaviors. The goal is to understand the impact of co-using these products in this population.

ClinicalTrials.govn=150
Open the research library
05 — Engage

Build the UK's most compliant cannabis business — with us.

Start a conversation
contact@medicexum.co.uk